肿瘤患者支持治疗的进展

邓婷; 巴一

doi:10.12354/j.issn.1000-8179.2022.20211712

肿瘤患者支持治疗的进展

doi: 10.12354/j.issn.1000-8179.2022.20211712

邓婷,
巴一^,

天津医科大学肿瘤医院消化肿瘤内科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中心（天津市300060）

详细信息

作者简介:
邓婷：专业方向为恶性消化肿瘤内科治疗，肿瘤支持治疗等

通讯作者:
巴一 bayi@tjmuch.com

计量
- 文章访问数: 448
- HTML全文浏览量: 221
- PDF下载量: 158
- 被引次数: 0
出版历程
- 收稿日期: 2021-11-15
- 录用日期: 2022-03-14
- 修回日期: 2022-02-13

Research progress on supportive care for cancer patients

Ting Deng,
Yi Ba^,

Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

More Information

Corresponding author: Yi Ba; E-mail: bayi@tjmuch.com

摘要

摘要: 肿瘤支持治疗是与肿瘤放疗、化疗和手术并重的治疗手段。肿瘤支持治疗包括从肿瘤诊断开始一直到生命结束的全程，其内容相当宽泛，且对于延长患者生存期，改善生存质量，节约医疗成本等均具有重要意义。随着研究的不断深入，肿瘤支持治疗在各领域均取得了一系列重要进展，其作用也越来越受到重视。尤为重要的是，医患认知从传统治疗理念发生根本性转变，使肿瘤支持治疗的发展前景焕发蓬勃生机。目前，肿瘤支持治疗逐渐向多学科整合、以患者为中心的个体化、全程化的管理及数字化方向发展。未来，随着学科分支的精细化和基础转化研究的不断深入，肿瘤患者的支持治疗必将形成一个完整的学科，造福广大的癌症患者。
- 肿瘤 /
- 支持治疗 /
- 进展
Abstract: Supportive care is equally important as radiotherapy, chemotherapy, and surgery in cancer treatment. The content of supportive care in cancer is quite broad and includes the entire process from the beginning of tumor diagnosis to the end of patients’ life. Effective tumor supportive care is helpful in prolonging patients’ survival, improving their quality of life, and decreasing medical costs. In recent years, with the advances in clinical and basic research, a series of important progress has been made in various areas of supportive care in cancer, and its role has attracted further attention. It is particularly important that the cognition of doctors and patients has fundamentally changed from the traditional treatment concept, making the development of supportive care a topical need. Currently, supportive care is gradually being developed toward multidisciplinary integration, patient-centered individualization, whole-process management, and digitalization. In the future, with the refinement of discipline branches and the deepening of basic translational research, supportive care in cancer will form an integrated system, from which more patients with cancer would benefit.
- cancer /
- supportive care /
- progress

HTML全文

参考文献(32)

[1]	Senn HJ. Quality of life in cancer patients: whose business is it anyway [J]? Support Care Cancer, 1993, 1(3): 115.
[2]	Olver I, Keefe D, Herrstedt J, et al. Supportive care in cancer-a MASCC perspective[J]. Support Care Cancer, 2020, 28(8):3467-3475. doi: 10.1007/s00520-020-05447-4
[3]	Hui D, Hannon BL, Zimmermann C, et al. Improving patient and caregiver outcomes in oncology: team-based, timely, and targeted palliative care[J]. CA Cancer J Clin, 2018, 68(5):356-376. doi: 10.3322/caac.21490
[4]	Hui D, Bruera E. Integrating palliative care into the trajectory of cancer care[J]. Nat Rev Clin Oncol, 2016, 13(3):159-171. doi: 10.1038/nrclinonc.2015.201
[5]	Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer[J]. N Engl J Med, 2010, 363(8):733-742. doi: 10.1056/NEJMoa1000678
[6]	Arnaud A, Grenier J, Boustany R, et al. Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer[J]. Support Care Cancer, 2021, 29(7):3735-3742. doi: 10.1007/s00520-020-05877-0
[7]	El-Jawahri A, Greer JA, Pirl WF, et al. Effects of early integrated palliative care on caregivers of patients with lung and gastrointestinal cancer: a randomized clinical trial[J]. Oncologist, 2017, 22(12): 1528-1534.
[8]	May P, Morrison RS, Murtagh FE. Current state of the economics of palliative and end-of-life care: a clinical view[J]. Palliat Med, 2017, 31(4):293-295. doi: 10.1177/0269216317695680
[9]	Adelson K, Paris J, Horton JR, et al. Standardized criteria for palliative care consultation on a solid tumor oncology service reduces downstream health care use[J]. J Oncol Pract, 2017, 13(5):e431-e440. doi: 10.1200/JOP.2016.016808
[10]	Bruera E, Hui D. Conceptual models for integrating palliative care at cancer centers[J]. J Palliat Med, 2012, 15(11):1261-1269. doi: 10.1089/jpm.2012.0147
[11]	Jordan K, Aapro M, Kaasa S, et al. European society for medical oncology (ESMO) position paper on supportive and palliative care[J]. Ann Oncol, 2018, 29(1):36-43. doi: 10.1093/annonc/mdx757
[12]	Lu ZH, Fang Y, Liu C, et al. Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: A phase Ⅲ randomized controlled trial[J]. J Clin Oncol, 2021, 39(7):748-756. doi: 10.1200/JCO.20.01254
[13]	Davis LE, Bubis LD, Mahar AL, et al. Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study[J]. Eur J Cancer, 2018, 101:1-11. doi: 10.1016/j.ejca.2018.06.006
[14]	Basch E. The missing voice of patients in drug-safety reporting[J]. N Engl J Med, 2010, 362(10):865-869. doi: 10.1056/NEJMp0911494
[15]	Basch E, Dueck AC, Rogak LJ, et al. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials[J]. JAMA Oncol, 2017, 3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749
[16]	Basch E, Wood WA, Schrag D, et al. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial[J]. Clin Trials, 2016, 13(3):331-337. doi: 10.1177/1740774515615540
[17]	Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment[J]. JAMA, 2017, 318(2):197-198. doi: 10.1001/jama.2017.7156
[18]	Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378(14):1277-1290. doi: 10.1056/NEJMoa1712126
[19]	Bubis LD, Davis L, Mahar A, et al. Symptom burden in the first year after cancer diagnosis: an analysis of patient-reported outcomes[J]. J Clin Oncol, 2018, 36(11): 1103-1111.
[20]	Hirpara DH, Gupta V, Davis LE, et al. Severe symptoms persist for Up to one year after diagnosis of stage Ⅰ-Ⅲ lung cancer: An analysis of Province-wide patient reported outcomes[J]. Lung Cancer, 2020, 142:80-89. doi: 10.1016/j.lungcan.2020.02.014
[21]	Ganz PA. The ‘three Ps’ of cancer survivorship care[J]. BMC Med, 2011, 9:14. doi: 10.1186/1741-7015-9-14
[22]	Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5):363-385. doi: 10.3322/caac.21565
[23]	Chow EJ, Ness KK, Armstrong GT, et al. Current and coming challenges in the management of the survivorship population[J]. Semin Oncol, 2020, 47(1):23-39. doi: 10.1053/j.seminoncol.2020.02.007
[24]	Tan SY, Turner J, Kerin-Ayres K, et al. Health concerns of cancer survivors after primary anti-cancer treatment[J]. Support Care Cancer, 2019, 27(10):3739-3747. doi: 10.1007/s00520-019-04664-w
[25]	Armes J, Crowe M, Colbourne L, et al. Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey[J]. J Clin Oncol, 2009, 27(36):6172-6179. doi: 10.1200/JCO.2009.22.5151
[26]	Alfano CM, Mayer DK, Bhatia S, et al. Implementing personalized pathways for cancer follow-up care in the United States: proceedings from an American cancer society-American society of clinical oncology summit[J]. CA Cancer J Clin, 2019, 69(3):234-247. doi: 10.3322/caac.21558
[27]	Alfano CM, Jefford M, Maher J, et al. Building personalized cancer follow-up care pathways in the United States: lessons learned from implementation in England, northern Ireland, and Australia[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 625-639.
[28]	Sinsky C, Colligan L, Li L, et al. Allocation of physician time in ambulatory practice: A time and motion study in 4 specialties[J]. Ann Intern Med, 2016, 165(11):753-760. doi: 10.7326/M16-0961
[29]	Curry J, Patterson M, Greenley S, et al. Feasibility, acceptability, and efficacy of online supportive care for individuals living with and beyond lung cancer: a systematic review[J]. Support Care Cancer, 2021, 29(11):6995-7011. doi: 10.1007/s00520-021-06274-x
[30]	Greer JA, Jacobs J, Pensak N, et al. Randomized trial of a tailored cognitive-behavioral therapy mobile application for anxiety in patients with incurable cancer[J]. Oncologist, 2019, 24(8):1111-1120. doi: 10.1634/theoncologist.2018-0536
[31]	Willems RA, Bolman CA, Mesters I, et al. Short-term effectiveness of a web-based tailored intervention for cancer survivors on quality of life, anxiety, depression, and fatigue: randomized controlled trial[J]. Psychooncology, 2017, 26(2):222-230. doi: 10.1002/pon.4113
[32]	Penedo FJ, Oswald LB, Kronenfeld JP, et al. The increasing value of eHealth in the delivery of patient-centred cancer care[J]. Lancet Oncol, 2020, 21(5):e240-e251. doi: 10.1016/S1470-2045(20)30021-8